Literature DB >> 34019286

Identifying and Validating MYC:Protein Interactors in Pursuit of Novel Anti-MYC Therapies.

Diana Resetca1, Alannah S MacDonald1, Tristan M G Kenney1,2, Yong Wei2, Cheryl H Arrowsmith1,2, Brian Raught1,3, Linda Z Penn4,5.   

Abstract

By identifying MYC protein-protein interactors, we aim to gain a deeper mechanistic understanding of MYC as a regulator of gene transcription and potent oncoprotein. This information can then be used to devise strategies for disrupting critical MYC protein-protein interactions to inhibit MYC-driven tumorigenesis. In this chapter, we discuss four techniques to identify and validate MYC-interacting partners. First, we highlight BioID, a powerful discovery method used to identify high-confidence proximal interactors in living cells. We also discuss bioinformatic prioritization strategies for the BioID-derived MYC-proximal complexes. Next, we discuss how protein interactions can be validated using techniques such as in vivo-in vitro pull-down assays and the proximity ligation assay (PLA). We conclude with an overview of biolayer interferometry (BLI), a quantitative method used to characterize direct interactions between two proteins in vitro. Overall, we highlight the principles of each assay and provide methodology necessary to conduct these experiments and adapt them to the study of interactors of additional proteins of interest.

Entities:  

Keywords:  BioID; Biolayer interferometry (BLI); Chromatin immunoprecipitation; Interactomes; MYC; Protein networks; Protein–protein interactions; Proximity ligation assay (PLA); Pull-down assay

Year:  2021        PMID: 34019286     DOI: 10.1007/978-1-0716-1476-1_4

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  38 in total

1.  X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors.

Authors:  Satish K Nair; Stephen K Burley
Journal:  Cell       Date:  2003-01-24       Impact factor: 41.582

2.  MYC Protein Interactome Profiling Reveals Functionally Distinct Regions that Cooperate to Drive Tumorigenesis.

Authors:  Manpreet Kalkat; Diana Resetca; Corey Lourenco; Pak-Kei Chan; Yong Wei; Yu-Jia Shiah; Natasha Vitkin; Yufeng Tong; Maria Sunnerhagen; Susan J Done; Paul C Boutros; Brian Raught; Linda Z Penn
Journal:  Mol Cell       Date:  2018-11-08       Impact factor: 17.970

3.  Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc.

Authors:  E M Blackwood; R N Eisenman
Journal:  Science       Date:  1991-03-08       Impact factor: 47.728

4.  Insights into the mechanism of heterodimerization from the 1H-NMR solution structure of the c-Myc-Max heterodimeric leucine zipper.

Authors:  P Lavigne; M P Crump; S M Gagné; R S Hodges; C M Kay; B D Sykes
Journal:  J Mol Biol       Date:  1998-08-07       Impact factor: 5.469

Review 5.  MYC degradation.

Authors:  Amy S Farrell; Rosalie C Sears
Journal:  Cold Spring Harb Perspect Med       Date:  2014-03-01       Impact factor: 6.915

6.  Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc.

Authors:  S E Salghetti; S Y Kim; W P Tansey
Journal:  EMBO J       Date:  1999-02-01       Impact factor: 11.598

7.  Discovery of WD Repeat-Containing Protein 5 (WDR5)-MYC Inhibitors Using Fragment-Based Methods and Structure-Based Design.

Authors:  Selena Chacón Simon; Feng Wang; Lance R Thomas; Jason Phan; Bin Zhao; Edward T Olejniczak; Jonathan D Macdonald; J Grace Shaw; Caden Schlund; William Payne; Joy Creighton; Shaun R Stauffer; Alex G Waterson; William P Tansey; Stephen W Fesik
Journal:  J Med Chem       Date:  2020-04-09       Impact factor: 7.446

8.  Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy.

Authors:  Huiying Han; Atul D Jain; Mihai I Truica; Javier Izquierdo-Ferrer; Jonathan F Anker; Barbara Lysy; Vinay Sagar; Yi Luan; Zachary R Chalmers; Kenji Unno; Hanlin Mok; Rajita Vatapalli; Young A Yoo; Yara Rodriguez; Irawati Kandela; J Brandon Parker; Debabrata Chakravarti; Rama K Mishra; Gary E Schiltz; Sarki A Abdulkadir
Journal:  Cancer Cell       Date:  2019-10-31       Impact factor: 31.743

9.  Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy.

Authors:  Marie-Eve Beaulieu; Toni Jauset; Daniel Massó-Vallés; Sandra Martínez-Martín; Peter Rahl; Loïka Maltais; Mariano F Zacarias-Fluck; Sílvia Casacuberta-Serra; Erika Serrano Del Pozo; Christopher Fiore; Laia Foradada; Virginia Castillo Cano; Meritxell Sánchez-Hervás; Matthew Guenther; Eduardo Romero Sanz; Marta Oteo; Cynthia Tremblay; Génesis Martín; Danny Letourneau; Martin Montagne; Miguel Ángel Morcillo Alonso; Jonathan R Whitfield; Pierre Lavigne; Laura Soucek
Journal:  Sci Transl Med       Date:  2019-03-20       Impact factor: 17.956

10.  Analysis of Myc-induced histone modifications on target chromatin.

Authors:  Francesca Martinato; Matteo Cesaroni; Bruno Amati; Ernesto Guccione
Journal:  PLoS One       Date:  2008-11-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.